{
    "2020-01-21": [
        [
            {
                "time": "2019-01-21",
                "original_text": "格隆汇港股聚焦(1.21)︱中国财险2019年净利预增35%到60% 海通证券预计年度归母净利润升80%到86%",
                "features": {
                    "keywords": [
                        "中国财险",
                        "净利预增",
                        "海通证券",
                        "归母净利润"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "保险"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-21",
                "original_text": "投资图谱：「2019新型冠状病毒」来袭 A股四大维度99股备受关注",
                "features": {
                    "keywords": [
                        "新型冠状病毒",
                        "A股",
                        "医药"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-01-21",
                "original_text": "第二批带量采购结果公布带动行情，游资趁机抛售医药股丨牛熊眼",
                "features": {
                    "keywords": [
                        "带量采购",
                        "医药股",
                        "游资抛售"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-01-21",
                "original_text": "复星医药：非执行董事王灿辞职",
                "features": {
                    "keywords": [
                        "复星医药",
                        "非执行董事",
                        "辞职"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-21",
                "original_text": "复星医药(02196.HK)委任非执行董事沐海宁担任审计委员会成员",
                "features": {
                    "keywords": [
                        "复星医药",
                        "非执行董事",
                        "审计委员会"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-21",
                "original_text": "复星医药(02196.HK)附属早期乳腺癌治疗药物获药品临床试验通知书",
                "features": {
                    "keywords": [
                        "复星医药",
                        "乳腺癌治疗",
                        "临床试验"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-21",
                "original_text": "智通港股通持股分析|1月21日",
                "features": {
                    "keywords": [
                        "港股通",
                        "持股分析"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-21",
                "original_text": "未来药物创新将走向何处？业内：3个方向值得参考",
                "features": {
                    "keywords": [
                        "药物创新",
                        "发展方向"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-01-19",
                "original_text": "【山证医药】医药行业周报（20190119）：集采常态化加快推进，行业逐步进入创新时代",
                "features": {
                    "keywords": [
                        "医药行业",
                        "集采常态化",
                        "创新时代"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}